Equine arthritis


What is equine arthritis?

Also known as degenerative joint disease (DJD), osteoarthritis or "OA," arthritis is the progressive deterioration of the articular cartilage, accompanied by changes in bone and soft tissues of the joint.¹



Arthritis starts with an inflamed joint and disruption of the "wear and repair" cycle:1

- **1.** Synovial (joint) membrane becomes inflamed.
- 2. Enzymes attack synovial fluid and cartilage.
- **3.** Healthy cartilage erodes.
- Bone rubs on bone, causing pain, inflammation and decreased range of motion.
- **5.** The cycle continues.



Learn about an FDA-approved treatment that helps break this debilitating cycle.

Please see Indications and Important Safety Information on the back and accompanying Full Prescribing Information.



Break the arthritis cycle

Treat the disease and not just the signs of arthritis.^{1,2}



Adequan[®] i.m. works in multiple ways to keep joints moving:^{3,4}

- **REDUCES** inflammation
- **RESTORES** joint lubrication
- **REPAIRS** cartilage
- **REVERSES** the disease process



INDICATIONS Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). Studies have not been conducted to establish safety in breeding horses. **WARNING:** Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. **CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. *Please see Full Prescribing Information attached to this piece or visit adequan.com.*

- 1. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
- 2. Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
- 3. Adequan® i.m. (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
- 4. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

All trademarks are the property of American Regent, Inc. © 2024, American Regent, Inc. PP-AI-US-1120





For Intramuscular Use In Horses



MULTI-DOSE

Solution 100 mg/mL in a 50 mL Preserved Multi-Dose Vial For Intramuscular Use In Horses Only. Not for Intra-Articular Use



CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 5 milliliters of Adequan[®] i.m. contains 500 mg of Polysulfated Glycosaminoglycan (PSGAG) and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.

PHARMACOLOGY: Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.

INDICATIONS: Adequan[®] i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

DOSAGE AND ADMINISTRATION: The recommended dose of Adequan[®] i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan[®] i.m. with other drugs or solvents.

CONTRAINDICATIONS: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.

WARNINGS: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.

PRECAUTIONS: The safe use of Adequan[®] i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

ANIMAL SAFETY: Toxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

STORAGE CONDITIONS: Store at 20°-25°C (68°-77°F); (See USP Controlled Room Temperature). Discard unused portion.

Dispose of spent needles in accordance with all federal, state and local environmental laws.

HOW SUPPLIED: Adequan[®] i.m. solution, 500 mg/5 mL (100 mg/mL) in a 5 mL single dose glass vial.

NDC 10797-995-70	5 mL Single Dose Vials	Packaged 7 vials per box
------------------	------------------------	--------------------------

AMERICAN REGENT, INC. ANIMAL HEALTH	Made in U.S.A. IN99501
Shirley, NY 11967	Rev. 9/2021
(1-888-354-4857)	MG #44455

Approved by FDA under NADA # 140-901

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each mL contains Polysulfated Glycosaminoglycan (PSGAG) 100 mg, Benzyl Alcohol 0.9% v/v as a preservative, and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. The solution is clear, colorless to slightly yellow.

PHARMACOLOGY: Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.

INDICATIONS: Adequan[®] i.m. Multi-Dose is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

DOSAGE AND ADMINISTRATION: Practice aseptic techniques in withdrawing each dose to decrease the possibility of post-injection bacterial infections. Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe. Use only sterile needles, and use each needle only once.

The vial stopper may be punctured a maximum of 10 times.

The recommended dose of Adequan[®] i.m. Multi-Dose in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan[®] i.m. Multi-Dose with other drugs or solvents.

CONTRAINDICATIONS: There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.

WARNINGS: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.

PRECAUTIONS: The safe use of Adequan[®] i.m. Multi-Dose in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.

SAFETY AND EFFICACY: Safety and efficacy studies utilizing Adequan® i.m. Multi-Dose were not performed. Adequan® i.m. Multi-Dose was approved based on the conclusion that the safety and effectiveness of Adequan® i.m. Multi-Dose will not differ from that demonstrated for the original formulation of Adequan® i.m.

ANIMAL SAFETY: Animal Safety studies utilizing Adequan[®] i.m. Multi-Dose were not performed. Safety studies were conducted in horses using the single dose formulation. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.

STORAGE CONDITIONS: Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Avoid prolonged exposure to temperatures \geq 40°C (104°F).

Use within 28 days of first puncture and puncture a maximum of 10 times. Dispose of spent needles in accordance with all federal, state and local environmental laws.

HOW SUPPLIED: Adequan[®] i.m. Multi-Dose solution, 5,000 mg/50 mL (100 mg/mL) in 50 mL multidose glass vials.

NDC 10797-959-01	50 mL Multi-Dose Vials	Packaged 1 vial per box
AMERICAN REGENT, INC.		Made in U.S.A.
ANIMAL HEALTH		IN959
Shirley, NY 11967		Rev. 9/2021
(1-888-354-4857)		MG #44453

Approved by FDA under NADA # 140-901